American Pharmacy News
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • Home
  • »
  • Stories
  • »
  • American Pharmacy News Reports

AHSP applauds 21st Century Cures Act

American Pharmacy News Reports | Jan 7, 2017
The 21st Century Cures Act was enacted to change the way the United States treats disease.

The American Journal of Health-System Pharmacy has applauded the 21st Century Cures Act was signed into law by President Barack Obama on Dec. 13. Read More »

Teva Pharmaceuticals agrees to pay $519 million settlement

Mark Iandolo | Jan 7, 2017
The settlement includes a penalty of $519 million.

Teva Pharmaceuticals Industries Ltd. (Teva) recently announced a settlement with the United States government related to allegations of violating the Foreign Corrupt Practices Act (FCPA) in Ukraine, Mexico and Russia. Read More »

Direct Relief airlifts 82 tons of medical aid to Haiti

Mark Iandolo | Jan 7, 2017
Cholera and other diseases have become rampant across Haiti since Hurricane Matthew in October.

Direct Relief recently announced that it airlifted 82 tons of medical aid to Haiti for the treatment of cholera and other diseases that have become rampant since Hurricane Matthew in October. Read More »

Aurinia partners with Lonza for the manufacture of voclosporin

American Pharmacy News Reports | Jan 7, 2017
Lonza will provide Aurinia with cGMP-grade voclosporin drug substance for use in Aurinia’s Phase III lupus nephritis clinical program.

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, recently partnered with Lonza for the manufacture of voclosporin active pharmaceutical ingredient (API). Read More »

Genentech study analyzing emicizumab for hemophilia A meets primary endpoint

American Pharmacy News Reports | Jan 7, 2017
Emicizumab prophylaxis significantly reduced the number of bleeds over time in people in this difficult-to-treat setting.

Genentech, a member of the Roche Group, recently announced that the primary endpoint for the Phase III HAVEN 1 study has been met. The study evaluates emicizumab prophylaxis in people 12 years of age or older with hemophilia A and inhibitors to factor VIII. Read More »

Express Scripts slated to present at health care summit

Carol Ostrow | Jan 5, 2017

The Express Scripts Holding Company recently revealed plans to present at the J.P. Morgan Healthcare Conference next week in San Francisco. Read More »

Bayer, Leica Biosystems to develop companion tests for cancer patients

Mark Iandolo | Jan 4, 2017
The tests will be based on the Bayer-developed automated BOND technology platform for novel targeted anti-cancer therapies.

Bayer recently announced an agreement with Leica Biosystems to collaborate on developing companion diagnostic tests based on tissue samples for cancer patients. Read More »

Pernix appoints Leung to board of directors

American Pharmacy News Reports | Jan 4, 2017
Pernix Therapeutics Holdings specializes in pain and central nervous system conditions.

Pernix Therapeutics Holdings Inc., a pharmaceutical company specializing in pain and central nervous system conditions, recently appointed Gabriel Leung to its board of directors. Read More »

Zynex expects to post $15 million in revenue for 2016

American Pharmacy News Reports | Jan 4, 2017
Zynex manufactures non-invasive medical devices.

Medical technology company Zynex updated its November orders, fourth-quarter estimate and a loan forbearance agreement. Read More »

Veloxis establishes warrant program for employees, board members

American Pharmacy News Reports | Jan 4, 2017
The total number of warrants awarded will be just over 2.8 million, which will give the right to subscription at $0.10 each.

Veloxis Pharmaceuticals will establish a warrant program for its board members and its employees with the Veloxis Board of Directors exercising, in part, an authorization pursuant to the Articles of Association. Read More »

Avella moves corporate headquarters to Phoenix

American Pharmacy News Reports | Jan 4, 2017
The move into the Phoenix facility will allow Avella to house its clinical, operational and administrative processes in one location.

Avella has moved its operations to a new 50,000-square-foot corporate headquarters in Phoenix. Read More »

Rebiotix treats first patient with microbe capsule

American Pharmacy News Reports | Jan 4, 2017

The biotech company Rebiotix Inc. recently announced that a patient has been treated for the first time with a capsule that delivers live microbes into the human intestinal tract. Read More »

AcelRx presents ARX-04 data at ASRA annual meeting

American Pharmacy News Reports | Jan 3, 2017
The presentation featured the first data presented from the ARX-04 trial.

AcelRx Pharmaceuticals presented results from its Phase 3 SAP303 study of ARX-04 at the 15th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine. Read More »

AzurRx teams with Mayoly Spindler for Phase II drug trial

American Pharmacy News Reports | Jan 3, 2017
The Phase II clinical trial will assess the safety and effectiveness of MS1819-SD for the treatment of patients who have exocrine pancreatic insufficiency.

AzurRx BioPharma has partnered with Mayoly Spindler to begin a Phase II clinical trial to assess the safety and effectiveness of MS1819-SD for the treatment of patients who have exocrine pancreatic insufficiency that is the result of chronic pancreatitis. Read More »

FDA approves Intrarosa for moderate to severe pain during intercourse

American Pharmacy News Reports | Jan 3, 2017
Intrarosa has been approved to treat postmenopausal women who experience pain during sex.

Intrarosa (prasterone), which is designed for women who experience moderate to severe pain during sex, has been approved by the U.S. Food and Drug Administration. Read More »

Boehringer Ingelheim releases INVICTAN-1 trial data

American Pharmacy News Reports | Jan 3, 2017
The INVICTAN-1 trial involved BI 695502.

Boehringer Ingelheim has released data from its Phase I INVICTAN-1 trial involving BI 695502, the company’s bevacizumab biosimilar candidate, which shows that the drug is a bioequivalent of Avastin, which is licensed in the U.S. and E.U. Read More »

Collegiate Inventors Competition names graduate, undergraduate winners

American Pharmacy News Reports | Jan 3, 2017
The Collegiate Inventors Competition recently named its 2016 winners.

The 2016 graduate and undergraduate student winners of the Collegiate Inventors Competition included inventions and innovations presented at the competition including the administration of therapeutic drugs at-home and engineered biological particles that destroy pesticides in residual crops. Read More »

PharaMar names Besman new chief operating officer

American Pharmacy News Reports | Dec 31, 2016
Pascal Besman will serve as PharaMar's new chief operating officer.

PharmaMar has named Pascal Besman as its new chief operating officer, effective immediately. Read More »

McKesson honors pharmacists’ contributions to health care

American Pharmacy News Reports | Dec 31, 2016
APhM, which is sponsored by American Pharmacists Association, is meant to bring awareness to the profession.

McKesson and Health Mart support the dedication of pharmacists across all practice settings and commend the American Pharmacists Association for celebrating pharmacists’ commitment to provide customers with extraordinary service. Read More »

Qapzola receives setback from FDA committee

American Pharmacy News Reports | Dec 31, 2016
The Oncologic Drugs Advisory Committee, which is part of the U.S. Food and Drug Administration, has voted that   Spectrum Pharmaceuticals' Qapzola has not displayed considerable indication of a more effective treatment compared to placebo for immediate in

The Oncologic Drugs Advisory Committee, which is part of the U.S. Food and Drug Administration, has voted that Spectrum Pharmaceuticals' Qapzola has not displayed considerable indication of a more effective treatment compared to placebo for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. Read More »

  • «
  • 1
  • 2
  • ...
  • 64
  • 65
  • 66 (current)
  • 67
  • 68
  • ...
  • 167
  • 168
  • »
Trending

Shaun Noorian, CEO of Empower Pharmacy

Empower Pharmacy CEO: Big pharmaceutical companies pay 'to make rules that are in favor' of their company and 'stifle competition'

Jim Smith President

PCCA receives Texas governor's corporate champion award for community service

Stephen Sherry, Acting Director for the National Library of Medicine

National Library of Medicine says compounded medications offer alternatives for patients with unique medical needs

Jim Smith President

PCCA honors excellence in pharmacy compounding at annual awards ceremony

 B. Douglas Hoey CEO

NCPA urges careful consideration of pharma tariffs to prevent shortages and cost increases

Copyright © 2025 American Pharmacy News. All Rights Reserved.

  • About
  • Contact
  • Privacy Policy
  • Terms of Service

Alerts Sign-up